{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:04:08Z","timestamp":1774526648285,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Osteoarthritis (OA) is a leading cause of chronic pain. As healthcare services struggle to meet demand to treat chronic pain, many individuals self-manage their symptoms. Probiotics and palmitoylethanolamide (PEA) may be promising therapeutic options because of their anti-inflammatory properties. PEA is an endogenously produced N-acylethanolamine, considered \u201cendocannabinoid-like\u201d due to its structural similarity to endocannabinoids. While it has non-direct influence on the endocannabinoid system, it primarily acts via non-cannabinoid pathways, most notably through activation of peroxisome proliferator-activated receptor alpha (PPAR\u03b1). PEA has demonstrated both analgesic (pain-relieving) and mood-modulating effects in preclinical studies, and preliminary clinical studies. To date, no clinical studies have investigated the combined use of PEA and probiotics for the treatment of OA pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multiple baseline design (MBD) study was used over 11 weeks to assess the individual effects in four participants recruited from a naturopathic practice. Participants were randomised into one of two pathways, both starting with a placebo phase, followed by an active intervention involving probiotics and PEA. This design allowed for the concealment and blinding of the introduction of active treatment in a double-blind manner. The primary outcome was daily pain scores using a Visual Analogue Scale (VAS). Secondary outcomes incorporated a patient-reported measure which was a patient specified functional scale. Other secondary outcomes assessed wellbeing, stress, and blood indicators of inflammation. Visual analysis of time series graphs and descriptive statistics\u00a0were used to analyse the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The graph demonstrated a clear pain reduction for one participant. Analyses also suggested improvements in patient-specified functional scales, wellbeing, and anxiety for all participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This small multiple\u2011baseline study suggests that a probiotics\u2011plus\u2011PEA regimen\u00a0may\u00a0support function and wellbeing in some individuals with OA; these\u00a0preliminary, hypothesis\u2011generating\u00a0findings warrant evaluation in larger, controlled studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial was registered with the Australian New Zealand Clinical Trials Registry on the 18th of January 2021. The registration number is ACTRN#:12621000039886.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12906-025-05187-0","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:45:06Z","timestamp":1771461906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9895-8142","authenticated-orcid":false,"given":"Isabelle","family":"Taye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-272X","authenticated-orcid":false,"given":"Joanne","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-4088","authenticated-orcid":false,"given":"Sandra","family":"Grace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"9991","key":"5187_CR1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0140-6736(14)60802-3","volume":"386","author":"S Glyn-Jones","year":"2015","unstructured":"Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. Lancet. 2015;386(9991):376\u201387.","journal-title":"Lancet"},{"issue":"9","key":"5187_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/ard.2004.025270","volume":"64","author":"MJ Benito","year":"2005","unstructured":"Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5187_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nrn.2017.5","volume":"18","author":"R Kuner","year":"2017","unstructured":"Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2017;18(2):113.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"5187_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cger.2010.03.001","volume":"26","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355\u201369.","journal-title":"Clin Geriatr Med"},{"issue":"S5","key":"5187_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5694\/j.1326-5377.2004.tb05906.x","volume":"180","author":"LM March","year":"2004","unstructured":"March LM, Bagga H. Epidemiology of osteoarthritis in Australia. Med J Aust. 2004;180(S5):6\u201310.","journal-title":"Med J Aust"},{"key":"5187_CR6","unstructured":"Chronic Pain Australia. Pain Colours Your World: 2024 National Pain Report - The social and economic cost of chronic pain. 2024."},{"issue":"5","key":"5187_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11926-022-01066-6","volume":"24","author":"CM Dunn","year":"2022","unstructured":"Dunn CM, Jeffries MA. The microbiome in osteoarthritis: a narrative review of recent human and animal model literature. Curr Rheumatol Rep. 2022;24(5):139\u201348.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"5187_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jbmr.2765","volume":"31","author":"CJ Steves","year":"2016","unstructured":"Steves CJ, Bird S, Williams FM, Spector TD. The microbiome and musculoskeletal conditions of aging: a review of evidence for impact and potential therapeutics. J Bone Miner Res. 2016;31(2):261\u20139.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"5187_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/pathogens2040606","volume":"2","author":"L Vitetta","year":"2013","unstructured":"Vitetta L, Coulson S, Linnane AW, Butt H. The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics. Pathogens. 2013;2(4):606\u201326.","journal-title":"Pathogens"},{"issue":"2","key":"5187_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/nu12020574","volume":"12","author":"A de Sire","year":"2020","unstructured":"de Sire A, de Sire R, Petito V, Masi L, Cisari C, Gasbarrini A, et al. Gut-joint axis: the role of physical exercise on gut microbiota modulation in older people with osteoarthritis. Nutrients. 2020;12(2):574.","journal-title":"Nutrients"},{"issue":"12","key":"5187_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261353","volume":"16","author":"E Chisari","year":"2021","unstructured":"Chisari E, Wouthuyzen-Bakker M, Friedrich AW, Parvizi J. The relation between the gut microbiome and osteoarthritis: a systematic review of literature. PLoS One. 2021;16(12):e0261353.","journal-title":"PLoS One"},{"issue":"1","key":"5187_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02427-9","volume":"23","author":"X Hao","year":"2021","unstructured":"Hao X, Shang X, Liu J, Chi R, Zhang J, Xu T. The gut microbiota in osteoarthritis: where do we stand and what can we do? Arthritis Res Ther. 2021;23(1):42.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"5187_CR13","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.joca.2015.03.014","volume":"23","author":"KH Collins","year":"2015","unstructured":"Collins KH, Paul HA, Reimer RA, Seerattan RA, Hart DA, Herzog W. Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development: studies in a rat model. Osteoarthritis Cartilage. 2015;23(11):1989\u201398.","journal-title":"Osteoarthritis Cartilage"},{"issue":"5","key":"5187_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3920\/BM2016.0207","volume":"8","author":"M Lei","year":"2017","unstructured":"Lei M, Guo C, Wang D, Zhang C, Hua L. The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: a randomised double-blind, placebo-controlled clinical trial. Benef Microbes. 2017;8(5):697\u2013703.","journal-title":"Benef Microbes"},{"issue":"1","key":"5187_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1046\/j.1440-1711.2000.00886.x","volume":"78","author":"K Kailasapathy","year":"2000","unstructured":"Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 2000;78(1):80\u20138.","journal-title":"Immunol Cell Biol"},{"key":"5187_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114468","volume":"161","author":"C Purdel","year":"2023","unstructured":"Purdel C, Ungurianu A, Adam-Dima I, Margin\u0103 D. Exploring the potential impact of probiotic use on drug metabolism and efficacy. Biomed Pharmacother. 2023;161:114468.","journal-title":"Biomed Pharmacother"},{"key":"5187_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodcont.2019.106872","volume":"108","author":"D Pradhan","year":"2020","unstructured":"Pradhan D, Mallappa RH, Grover S. Comprehensive approaches for assessing the safety of probiotic bacteria. Food Control. 2020;108:106872.","journal-title":"Food Control"},{"key":"5187_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00608","volume":"7","author":"R Mart\u00edn","year":"2016","unstructured":"Mart\u00edn R, Laval L, Chain F, Miquel S, Natividad J, Cherbuy C, et al. Bifidobacterium animalis ssp. Lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice. Front Microbiol. 2016;7:608.","journal-title":"Front Microbiol"},{"issue":"2","key":"5187_CR19","first-page":"143","volume":"8","author":"JA Drisko","year":"2003","unstructured":"Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev. 2003;8(2):143\u201355.","journal-title":"Altern Med Rev"},{"key":"5187_CR20","doi-asserted-by":"publisher","unstructured":"Taye I, Bradbury J, Grace S, Avila C. Probiotics for pain of osteoarthritis; an N-of-1 trial of individual effects. Complement Ther Med. 2020;54:102548. https:\/\/doi.org\/10.1016\/j.ctim.2020.102548.","DOI":"10.1016\/j.ctim.2020.102548"},{"issue":"4","key":"5187_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/futurepharmacol3040058","volume":"3","author":"MGM S\u00e1 MCId, Castor","year":"2023","unstructured":"S\u00e1 MCId, Castor MGM. Therapeutic use of palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator. Future Pharmacol. 2023;3(4):951\u201377.","journal-title":"Future Pharmacol"},{"key":"5187_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OARRR.S93516","volume":"8","author":"A Sharma","year":"2016","unstructured":"Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. Open Access Rheumatol. 2016;8:103\u201313.","journal-title":"Open Access Rheumatol"},{"issue":"6","key":"5187_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061271","volume":"13","author":"SV Di","year":"2025","unstructured":"Di SV, Luca S Jr., D\u2019Angelo M, Monaco F, Steardo L. Palmitoylethanolamide: a multifunctional molecule for neuroprotection, chronic pain, and immune modulation. Biomedicines. 2025;13(6):1271.","journal-title":"Biomedicines"},{"issue":"9","key":"5187_CR24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1526-4637.2012.01432.x","volume":"13","author":"A Gatti","year":"2012","unstructured":"Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121\u201330.","journal-title":"Pain Med"},{"issue":"1","key":"5187_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10787-024-01623-8","volume":"33","author":"A Das","year":"2025","unstructured":"Das A, Balakrishnan P. Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. Inflammopharmacology. 2025;33(1):121\u201333.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"5187_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1871527311312010006","volume":"12","author":"HS Hansen","year":"2013","unstructured":"Hansen HS. Effect of diet on tissue levels of palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013;12(1):17\u201325.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"5187_CR27","first-page":"151","volume":"2013","author":"JK Hesselink","year":"2013","unstructured":"Hesselink JK, de Boer T, Witkamp R, Palmitoylethanolamide. A natural Body-Own Anti-Inflammatory Agent, effective and safe against influenza and common cold. Int J Inflam. 2013;2013:151\u201328.","journal-title":"Int J Inflam"},{"key":"5187_CR28","volume":"7","author":"E Gugliandolo","year":"2020","unstructured":"Gugliandolo E, Peritore A, Piras C, Cuzzocrea S, Crupi R. Palmitoylethanolamide and related aliamides: prohomeostatic lipid compounds for animal health and wellbeing. Vet Sci. 2020;7:78.","journal-title":"Vet Sci"},{"issue":"5","key":"5187_CR29","first-page":"353","volume":"20","author":"BB Artukoglu","year":"2017","unstructured":"Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017;20(5):353\u201362.","journal-title":"Pain Physician"},{"issue":"2","key":"5187_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/fsn3.392","volume":"5","author":"ER Nestmann","year":"2017","unstructured":"Nestmann ER. Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. Food Sci Nutr. 2017;5(2):292\u2013309.","journal-title":"Food Sci Nutr"},{"issue":"4","key":"5187_CR31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bcp.13020","volume":"82","author":"L Gabrielsson","year":"2016","unstructured":"Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5187_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40122-024-00685-4","volume":"14","author":"G Varrassi","year":"2025","unstructured":"Varrassi G, Rekatsina M, Leoni MLG, Cascella M, Finco G, Sardo S, et al. A decades-long journey of palmitoylethanolamide (PEA) for chronic neuropathic pain management: a comprehensive narrative review. Pain Ther. 2025;14(1):81\u2013101.","journal-title":"Pain Ther"},{"issue":"12","key":"5187_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40266-017-0506-2","volume":"34","author":"F Germini","year":"2017","unstructured":"Germini F, Coerezza A, Andreinetti L, Nobili A, Rossi PD, Mari D, et al. N-of-1 randomized trials of ultra-micronized palmitoylethanolamide in older patients with chronic pain. Drugs Aging. 2017;34(12):941\u201352.","journal-title":"Drugs Aging"},{"issue":"2","key":"5187_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1037\/h0074329","volume":"14","author":"M Freyd","year":"1923","unstructured":"Freyd M. The graphic rating scale. J Educ Psychol. 1923;14(2):83\u2013102.","journal-title":"J Educ Psychol"},{"issue":"1","key":"5187_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2519\/jospt.2012.3727","volume":"42","author":"KK Horn","year":"2012","unstructured":"Horn KK, Jennings S, Richardson G, Vliet DV, Hefford C, Abbott JH. The patient-specific functional scale: psychometrics, clinimetrics, and application as a clinical outcome measure. J Orthop Sports Phys Ther. 2012;42(1):30\u201342.","journal-title":"J Orthop Sports Phys Ther"},{"key":"5187_CR36","unstructured":"The International Wellbeing Group. Personal wellbeing index (5th Edition). 2013."},{"key":"5187_CR37","unstructured":"Aghayousefi A, Alipour A, Sharif N. Reliability and validity of the personal well-being index - adult in mothers of mentally retarded students in north of Tehran-Iran. Iran J Psychiatry Behav Sci. 2011;5(2):106\u201313."},{"key":"5187_CR38","unstructured":"NovoPsych. Personal Wellbeing Index \u2013 Adult \u2013 5 (PWI-A). 2023 [Available from: https:\/\/novopsych.com.au\/assessments\/well-being\/personal-wellbeing-index-adult-5-pwi-a\/."},{"key":"5187_CR39","doi-asserted-by":"crossref","unstructured":"Lovibond SH, Lovibond PF. Manual for the depression anxiety & stress scales (2nd Edition). 1995.","DOI":"10.1037\/t01004-000"},{"key":"5187_CR40","doi-asserted-by":"crossref","unstructured":"Henry JD, Crawford JR. The short-form version of the depression anxiety stress scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005;44(Pt 2):227\u201339.","DOI":"10.1348\/014466505X29657"},{"key":"5187_CR41","doi-asserted-by":"crossref","unstructured":"Wood BM, Nicholas MK, Blyth F, Asghari A, Gibson S. The utility of the short version of the depression anxiety stress scales (DASS-21) in elderly patients with persistent pain: does age make a difference? Pain Med. 2010;11(12):1780\u201390.","DOI":"10.1111\/j.1526-4637.2010.01005.x"},{"issue":"2","key":"5187_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejim.2007.04.026","volume":"19","author":"F Karadag","year":"2008","unstructured":"Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008;19(2):104\u20138.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"5187_CR43","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3899\/jrheum.081188","volume":"36","author":"CS Crowson","year":"2009","unstructured":"Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. 2009;36(8):1606\u201310.","journal-title":"J Rheumatol"},{"issue":"1","key":"5187_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","volume":"34","author":"D Davalos","year":"2012","unstructured":"Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43\u201362.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"5187_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1039\/c4ib00173g","volume":"7","author":"DB Kell","year":"2015","unstructured":"Kell DB, Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol (Camb). 2015;7(1):24\u201352.","journal-title":"Integr Biol (Camb)"},{"key":"5187_CR46","doi-asserted-by":"publisher","unstructured":"Mousa A, Misso M, Teede H, Scragg R, de Courten B. Effect of vitamin D supplementation on inflammation: protocol for a systematic review. BMJ Open 2016;6(4). https:\/\/doi.org\/10.1136\/bmjopen-2015-010804.","DOI":"10.1136\/bmjopen-2015-010804"},{"key":"5187_CR47","unstructured":"Critical Appraisal Skills Programme. CASP Randomised Controlled Trial Standard Checklist. 2022."},{"issue":"1","key":"5187_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.","journal-title":"BMC Med"},{"issue":"2","key":"5187_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cger.2021.11.001","volume":"38","author":"MJ Thomas","year":"2022","unstructured":"Thomas MJ, Guillemin F, Neogi T. Osteoarthritis flares. Clin Geriatr Med. 2022;38(2):239\u201357.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"5187_CR50","first-page":"1648","volume":"30","author":"T Pham","year":"2003","unstructured":"Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30(7):1648\u201354.","journal-title":"J Rheumatol"},{"issue":"3","key":"5187_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030644","volume":"13","author":"J Nijs","year":"2024","unstructured":"Nijs J, Malfliet A, Roose E, Lahousse A, Van Bogaert W, Johansson E, et al. Personalized multimodal lifestyle intervention as the best-evidenced treatment for chronic pain: state-of-the-art clinical perspective. J Clin Med. 2024;13(3):644.","journal-title":"J Clin Med"},{"issue":"16","key":"5187_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12161655","volume":"12","author":"KJ Liddiard","year":"2024","unstructured":"Liddiard KJ, Brown CA, Raynor AJ. Positive association between patients\u2019 perception of chronic pain rehabilitation as a personally meaningful experience and the flourishing aspect of well-being. Healthcare. 2024;12(16):1655.","journal-title":"Healthcare"},{"issue":"2","key":"5187_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/papr.13168","volume":"23","author":"T Gershoni","year":"2023","unstructured":"Gershoni T, Pud D, Aviram J, Eisenberg E. Wellness of patients with chronic pain is not only about pain intensity. Pain Pract. 2023;23(2):145\u201354.","journal-title":"Pain Pract"},{"key":"5187_CR54","doi-asserted-by":"crossref","unstructured":"Abboud M, Rizk R, AlAnouti F, Papandreou D, Haidar S, Mahboub N. The health effects of vitamin D and probiotic Co-Supplementation: A systematic review of randomized controlled trials. Nutrients. 2020;13(1).","DOI":"10.3390\/nu13010111"},{"key":"5187_CR55","doi-asserted-by":"crossref","unstructured":"Castagliuolo I, Scarpa M, Brun P, Bernabe G, Sagheddu V, Elli M, et al. Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice. Ann Microbiol. 2021;71(1):42.","DOI":"10.1186\/s13213-021-01655-3"},{"key":"5187_CR56","doi-asserted-by":"crossref","unstructured":"Axling U, \u00d6nning G, Combs MA, Bogale A, H\u00f6gstr\u00f6m M, Svensson M. The effect of Lactobacillus plantarum 299v on iron status and physical performance in female iron-Deficient athletes: A randomized controlled trial. Nutrients. 2020;12(5).","DOI":"10.3390\/nu12051279"},{"issue":"1","key":"5187_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/rapm-2020-101898","volume":"46","author":"D Diep","year":"2021","unstructured":"Diep D, Chen KJQ, Kumbhare D. Ultrasound-guided interventional procedures for myofascial trigger points: a systematic review. Reg Anesth Pain Med. 2021;46(1):73\u201380.","journal-title":"Reg Anesth Pain Med"},{"key":"5187_CR58","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105\u201321.","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"5187_CR59","doi-asserted-by":"crossref","unstructured":"Chisari E, Wouthuyzen-Bakker M, Friedrich AW, Parvizi J. The relation between the gut Microbiome and osteoarthritis: A systematic review of literature. PLoS ONE. 2021;16(12).","DOI":"10.1371\/journal.pone.0261353"},{"issue":"11","key":"5187_CR60","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.1038\/s41380-021-01147-5","volume":"26","author":"A Minichino","year":"2021","unstructured":"Minichino A, Jackson MA, Francesconi M, Steves CJ, Menni C, Burnet PWJ, et al. Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia\/amotivation in a general population cohort. Mol Psychiatry. 2021;26(11):6269\u201376.","journal-title":"Mol Psychiatry"},{"key":"5187_CR61","doi-asserted-by":"crossref","unstructured":"Esposito G, Corpetti C, Pesce M, Seguella L, Annunziata G, Del Re A, et al. A palmitoylethanolamide producing Lactobacillus paracasei improves Clostridium difficile toxin A-induced colitis. Front Pharmacol. 2021;12:639\u2013728.","DOI":"10.3389\/fphar.2021.639728"},{"key":"5187_CR62","doi-asserted-by":"crossref","unstructured":"Moludi J, Alizadeh M, Lotfi Yagin N, Pasdar Y, Nachvak SM, Abdollahzad H, et al. New insights on atherosclerosis: a cross-talk between endocannabinoid systems with gut microbiota. J Cardiovasc Thorac Res. 2018;10(3):129\u201337.","DOI":"10.15171\/jcvtr.2018.21"},{"issue":"1","key":"5187_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/can.2016.0001","volume":"1","author":"NV DiPatrizio","year":"2016","unstructured":"DiPatrizio NV. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 2016;1(1):67\u201377.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"5187_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrendo.2015.211","volume":"12","author":"PD Cani","year":"2016","unstructured":"Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, et al. Endocannabinoids - at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016;12(3):133\u201343.","journal-title":"Nat Rev Endocrinol"},{"key":"5187_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2010.46","volume":"6","author":"GG Muccioli","year":"2010","unstructured":"Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.","journal-title":"Mol Syst Biol"},{"issue":"4","key":"5187_CR66","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ibd\/izy014","volume":"24","author":"DG Couch","year":"2018","unstructured":"Couch DG, Maudslay H, Doleman B, Lund JN, O\u2019Sullivan SE. The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018;24(4):680\u201397.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"5187_CR67","doi-asserted-by":"publisher","first-page":"E917","DOI":"10.1210\/jc.2011-3018","volume":"97","author":"P Monteleone","year":"2012","unstructured":"Monteleone P, Piscitelli F, Scognamiglio P, Monteleone AM, Canestrelli B, Di Marzo V, et al. Hedonic eating is associated with increased peripheral levels of Ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab. 2012;97(6):E917\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"5187_CR68","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/ibd\/izz017","volume":"25","author":"DG Couch","year":"2019","unstructured":"Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O\u2019Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-a randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis. 2019;25(6):1006\u201318.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"5187_CR69","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.amepre.2007.03.020","volume":"33","author":"NG Hawkins","year":"2007","unstructured":"Hawkins NG, Sanson-Fisher RW, Shakeshaft A, D\u2019Este C, Green LW. The multiple baseline design for evaluating population-based research. Am J Prev Med. 2007;33(2):162\u20138.","journal-title":"Am J Prev Med"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05187-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:03:19Z","timestamp":1774522999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-025-05187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5187"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05187-0","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Southern Cross University Human Research Ethics Committee (2020\/149). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of de-identified information was obtained from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}